Background. Herpes simplex virus type 2 (HSV-2) is a common cause of acute and recurrent aseptic meningitis. Our aim was to determine the impact of antiviral suppression on recurrence of meningitis and to delineate the full spectrum of neurological complications.
Herpes simplex virus type 2 (HSV-2) infection is a common sexually transmitted disease with a seroprevalence of 10%-25% in Sweden [1, 2] . The virus is neurotropic and causes neurological complications, primarily clinical meningitis with or without mucocutaneous lesions [3] [4] [5] [6] . HSV-2 is one of the major causes of aseptic meningitis, comprising up to 20% of consecutive cases tested with polymerase chain reaction (PCR) on cerebrospinal fluid (CSF) samples [7, 8] .
HSV meningitis carries the risk of a broad spectrum of future neurological morbidity, including recurrent meningitis, myelitis, and radiculitis [9] . In one study, one-third of 40 patients suffered from recurrent neurological symptoms within the first year after HSV meningitis [10] . Recurrent lymphocytic meningitis is mainly caused by HSV-2 [11] and is estimated to occur in 20%-30% of cases after primary HSV meningitis [3, 9, 10, 12] .
Suppressive antiviral therapy has been studied extensively in genital herpes and proved to be effective in diminishing the frequency of genital HSV infection recurrences [13] . A daily dose of 0.5 g of valacyclovir is effective for preventing genital herpes recurrences. In patients with frequent recurrences, a twice-daily dosage is beneficial [14] .
However, in meningitis, neither antiviral treatment in the acute phase nor suppressive therapy has been assessed in controlled trials. Nevertheless, antiviral treatment with 1 g of valacyclovir 3 times daily for 1 week is often used as acute phase treatment. Successful prevention of meningitis and other neurological symptoms with antiviral suppression has been reported in small case series [15, 16] .
In this randomized trial, which followed up patients for 2 years after HSV-2 meningitis, the aim was to determine the impact of antiviral suppression with 0.5 g of valacyclovir twice daily for 1 year on recurrence of meningitis and to delineate the full spectrum of neurological complications.
METHODS

Patients
Consecutive patients (.18 years of age) with symptoms of viral meningitis and CSF pleocytosis levels of .5 3 10 6 cells/L with an HSV-2 infection etiology were included. The etiology was verified by (1) detection of HSV-2 DNA in the CSF by PCR, (2) preceding or concurrent virologically verified HSV-2 lesions in the genital or lumbosacral region, or (3) a history of previous aseptic meningitis of herpetic or unknown origin and positive HSV-2 serology in the acute phase serum sample. For criteria 2 and 3, negative results in bacterial culture and PCR for enterovirus in CSF and negative serology results for tick-borne encephalitis virus were compulsory. Exclusion criteria included the following: (1) immunosuppression, (2) human immunodeficiency virus (HIV) infection, (3) pregnancy, (4) no protection against pregnancy in female sexually active patients, (5) hepatic impairment (aspartate aminotransferase [AST] or alanine aminotransferase [ALT] levels .5 times the upper limit of normal), (6) impaired renal function (estimated creatine clearance of #30 mL/minute), (7) intolerance to acyclovir or valacyclovir, (8) probenicid treatment, (9) systemic antiviral therapy with an antiherpetic effect or immunomodulatory therapy, (10) malabsorption, and (11) other ongoing investigational drug treatment.
The study was approved by the ethics committees of each institution, and all participants gave their written informed consent.
Procedures
We conducted a prospective, randomized, double-blind, placebocontrolled multicenter trial in Sweden. The prespecified primary, secondary, and tertiary objectives are presented in Table 1 . The study participants were enrolled at 9 departments of infectious diseases from November 2000 through January 2005 with a follow-up period of 2 years.
Patients were asked for their history of genital herpes and any previous meningitis, and thorough neurological examinations as well as assessments of skin and mucous membranes were performed by the investigating physician. Blood chemistry analyses (hemoglobin level, leukocyte count, thrombocyte count, differential counts, sodium level, potassium level, creatinine level, bilirubin level, AST level, and ALT level) were performed.
CSF samples and vesicle materials were analyzed for HSV-1 and HSV-2 DNA by use of a qualitative nested PCR as described elsewhere [17, 18] or a quantitative TaqMan PCR [19] [20] [21] at the regional clinical virological laboratories at the study sites.
Serum samples were analyzed for HSV-1 and HSV-2 typecommon and type-specific immunoglobulin G (IgG) by use of antigens from HSV-2 glycoprotein G and HSV-1 glycoprotein D, respectively [22, 23] . Acute phase treatment of HSV meningitis with 1 g of valacyclovir 3 times daily was initiated at admission or as soon as an HSV-2 infection etiology was confirmed clinically and/or virologically, and treatment was continued for 1 week. Participants were assigned to the placebo group or the valacyclovir suppression group by means of a computer-generated randomization protocol. The dosage chosen (0.5 g twice daily orally) is consistent with that often recommended for HSV suppression in immunocompromised patients [13, 24] . GlaxoSmithKline supplied the drug and placebo tablets in sealed packages.
The stratification was made from a clinical point of view. Primary HSV-2 meningitis was defined as first episode of HSV-2 meningitis according to the etiology criteria 1 or 2 described above. Recurrent HSV-2 meningitis was defined as the presence of at least 1 earlier episode of verified HSV-2 meningitis or viral meningitis of unknown origin along with positive HSV-2 serology result (criterion 3).
To ensure an even distribution within each stratum, a randomization request was faxed to the central unit at the Karolinska Pharmacy, and a stratified randomization in blocks according to the patient groups was performed. The study drug was started 0-3 days after completion of the acute phase treatment. Participants, clinicians, and pharmacologists were all unaware of the allocated study treatment. The code was not disclosed at any time to the study investigators until the last included patient had been followed up for 2 years and the statistical analyses were performed.
The patients continued with valacyclovir suppression or placebo for 1 year. Recurrence of meningitis was treated openly with 1 g of valacyclovir 3 times daily orally for 1 week, replaced by 5 mg/kg acyclovir 3 times daily intravenously in case of nausea or vomiting. Meanwhile, the randomized study treatment was temporarily withdrawn. In mucocutaneous recurrences only, treatment was generally avoided. In cases of severe genital herpes, 0.5 g of valacyclovir twice daily was given for 3-5 days. A similar policy was applied during the second year of follow-up.
Clinical investigation and blood chemistry analyses were performed at weeks 4-6 and after 12 and 24 months. Episodes of meningitis as well as episodes of mucocutaneous lesions were recorded. Verified recurrent meningitis was defined as clinical symptoms of meningitis and CSF pleocytosis levels of .5 3 10 6 cells/L. Probable recurrent meningitis was defined as clinical acute meningitis (headache, nausea, vomiting, hypersensitivity to light and noise neck stiffness) without lumbar puncture performed, or lack of pleocytosis, and no reasonable cause of the symptoms other than HSV infection. Genital herpes recurrence was defined as genital lesions with HSV detected by PCR or genital herpetic lesions reported by the patient.
The patients received diary cards to record adverse experiences, recurrences of herpetic lesions, or signs of meningitis, as well as missed doses of drug, as a memory support. The study nurse called the patient monthly to check on the tolerability of the drug and the presence or absence of any symptoms, using a structured questionnaire.
The following symptoms were specifically asked about (1) headache; (2) symptoms from the central nervous system (CNS) such as concentration difficulties, irritability, fatigue, hypersensitivity to light and noise, sleep disturbances, and influence on libido or sexual potency; (3) symptoms from the peripheral nervous system (PNS) such as radiating pain, skinsensitive defects, and muscular weakness; (4) symptoms from the autonomous nervous system (ANS) such as urinary or anorectal dysfunction; and (5) herpetic lesions in the genital or lumbosacral region.
Compliance was controlled in 2 ways: (1) by the patient's report on missed doses at the monthly telephone call and (2) by the investigating doctor or nurse who recorded and counted the tablets every 3 months.
Safety, tolerability, and discontinuation related to adverse events were recorded, as well as deviations of laboratory test results. Data were entered into an electronic case report form from a written one. Thereafter a central review of the datawas performed and discrepancies were returned to the investigational sites for clarification.
Statistical Analyses
We assessed time to recurrence, the primary endpoint, by use of Kaplan-Meier estimation and log-rank tests. In this analysis, participants with .1 recurrence were censored on their first recurrence. Categorical data were analyzed using v 2 tests.
Hazard ratios (HRs) and 95% confidence interval (CIs) were estimated through Cox proportional hazards regression. Statistical significance was set at a 5 .05. The sample size for this study was predicated on detection of a difference of 20% of recurrences of HSV-2 meningitis between the valacyclovir and placebo groups. On the basis of a calculated power of 80% and a significance level of 5%, we estimated that a minimum sample size of 86 patients would be needed. To compensate for patients who were not fully evaluable, the number of patients was increased by about 20%.
RESULTS
A total of 101 patients met the eligibility criteria. All patients had symptoms of viral meningitis and CSF pleocytosis levels of .5 3 10 6 cells/L. The HSV-2 infection diagnoses were based on DNA detection by PCR in the CSF samples in 87 case patients (valacyclovir group, n 5 44; placebo group, n 5 43), or concurrent virologically verified HSV-2 lesions or a history of previous aseptic meningitis of herpetic or unknown origin and positive HSV-2 IgG result at inclusion in 14 case patients (valacyclovir group, n 5 6; placebo group, n 5 8). Patients were randomly allocated to treatment with study drug or placebo ( Figure 1 ). Thirty-eight additional patients with diagnosed herpes meningitis were not included due to consent refusal or withdrawal, desire to become pregnant, immunosuppression, hepatic impairment or impaired renal function, severe anemia, intolerance to valacyclovir, geographical inconvenience, and missed or incorrect screening procedure. No patient had other neurological disease at inclusion or exclusion. Demographic data, clinical history of meningitis and/or genital herpes, and type-specific HSV-1 and HSV-2 serology results at baseline are presented in Table 2 . The patients with recurrent herpetic disease had a history of herpes for 1-31 years (median, 12 years). The majority of the patients were female. However, the sex distribution was equal in both groups, as was the number of patients with a clinical history of previous meningitis and/or genital herpes. The majority of patients tested negative for HSV-1 IgG, and the small number of patients who tested positive for HSV-1 IgG at baseline were equally distributed.
Eighty-three of the 101 patients were $ 75% compliant during 12 months of follow-up. Eighteen patients discontinued the medication, 5 in the valacyclovir group and 13 in the placebo group (Figure 1) .
The reasons for discontinuation were pregnancy (n 5 4) or desire to become pregnant (n 5 1), side effects (n 5 5), psychosocial reasons (n 5 5), new diagnosis of syringomyelia (n 5 1), frequent recurrences of genital herpes (n 5 1), and new episode of acute meningitis (n 5 1). The median time to discontinuation of therapy was 2 months (range, 0-7 months) in the valacyclovir group and 3.5 months (range, 1-7 months) in the placebo group. All patients underwent the scheduled monthly assessments and doctor's visits during the first year. During the second year, 4 patients were lost to follow-up.
Recurrence of HSV meningitis, verified and probable, was found in a nonsignificantly higher rate in the valacyclovir group than in the placebo group (HR, 1.86 [95% CI, .78-4.43]) ( Figure 2 ; Table 3 ) during the first year when subjects were taking the study drug. During the second year, the risk was significantly higher among patients previously exposed to valacyclovir (HR, 3.29 [95% CI, 10.06-10.21]) (Figure 2 ; Table 3 ). The difference remained when verified and probable meningitides were analyzed separately (data not shown). As an ancillary analysis, a comparison between the subgroups of patients who were .90% compliant within the groups (valacyclovir group, n 5 21; placebo group, n 5 16) was made and yielded results equivalent to those in the analysis of the patients with .75% compliance (data not shown).
In total, 48 meningitis episodes (16 verified and 32 probable) occurred during the 2 years of observation. Thirty-two patients (31.6%) had 1-4 episodes of meningitis. A cluster of episodes was observed in the valacyclovir group after drug cessation. The distribution of the meningitis episodes in the 2 groups during the first and second year is shown in Figure 3 .
With regard to headache and symptoms other than meningitis from the CNS, PNS, or ANS, a considerable morbidity was noted in both groups, but no statistically significant difference was shown between the groups (Table 3) .
Mucocutaneous recurrences occurred frequently during the first year in both groups, but significantly more patients had recurrences in the placebo group than in the valacyclovir group (Table 4 ). In the total cohort, 78% of the patients had recurrent herpetic manifestations, genital and/or meningeal, during the study period of 2 years.
Meningitis treatment was given without any significant difference in the type of antiviral, administration, or duration between the groups during the first and second years. During the first year, 3 treatments were given to 3 patients in the valacyclovir group and 8 treatments to 7 patients in the placebo group. During the second year, 6 treatments were given to 5 patients in the valacyclovir group and 3 treatments to 3 patients in the placebo group.
Genital herpes treatments were nonsignificantly more common in the placebo group than in the valacyclovir group (27 vs 20 patients, respectively; P 5 .19). In total, there were 96 reported recurrences in the placebo group and 49 in the valacyclovir group, and the number of treatment episodes was 27 and 15, respectively.
Adverse events possibly related to the study were recorded in 15 patients (30%) in the valacyclovir group and 9 (17.6%) in the placebo group (P 5 .14). Exanthema was the most commonly recorded adverse event. Two men, one in each group, suffered from profound sweating. Other adverse events were loose stools, angioedema, and palpitations.
Serious adverse events occurred in 6 patients; none were considered to be related to the study medication. In the valacyclovir group, 1 patient developed serious kidney disease, 1 patient was diagnosed with syringomyelia, and 3 others were hospitalized due to surgical abortion, surgery for inguinal hernia, or pyelonephritis. In the placebo group, 1 patient was hospitalized due to a probable postpunctional headache. 
DISCUSSION
This large prospective, double-blind, randomized controlled trial is the first to investigate the impact of antiviral suppression in patients with primary and recurrent HSV-2 meningitis. The 2-year study also allowed delineation of the natural course of symptoms, including a broad spectrum of neurological morbidity following HSV meningitis, which was hitherto lacking. We found no effect of antiviral suppression with 0.5 g of valacyclovir twice daily on the risk of recurrence of meningitis. The lack of a prohibiting effect was not due to any of the following confounding factors: age, sex, stratum, or previous herpetic disease (clinically and serologically determined), which were equally distributed in the 2 groups. The suppressive dose might not have been adequate for preventing meningitis recurrences in this particular cohort of patients, although it was higher than normal for genital recurrences [14] , being equal to the one recommended for immunocompromised patients [13, 24] and given twice daily, which has been found to be beneficial compared with once-daily regimens [25] . The dosage was, however, sufficient for decreasing recurrences of genital herpes. The acyclovir concentrations were not measured in the present study, but the levels achieved may have been suboptimal in protecting against further spread to the CNS. Previous studies have shown that even valacyclovir in the dosage of 1 g 3 times daily given to patients with multiple sclerosis resulted in only moderate concentrations in the CSF [26] . Recurrences were actually found in a greater number of patients during the first year in the actively treated group, but the difference was not statistically significant. The tendency of a higher risk of meningitis might reflect the possibility that these individuals, although randomly allocated, happened to be more prone to reactivation of meningitis.
During the second year after cessation of suppression, meningitis episodes occurred earlier and significantly more often in the group of patients previously treated with valacyclovir. The occurrence of a cluster of meningitis episodes at the beginning of the second year in the arm of patients with previous antiviral suppression is suggestive of a rebound effect of cessation of active drug, which might indicate that the drug has had some, but not a sufficient, suppressive effect during the first year. In the valacyclovir group, the immune system was less stimulated by mucocutaneous recurrences; such stimulation might play a protective role against meningitis recurrences.
The cohort studied seems to be at high risk of symptomatic herpes recurrences in general, as 78% of patients had recurrences (meningeal and/or genital) during the study period. One reason for this might be the female predominance in HSV-2 meningitis as demonstrated in this and previous studies [4, 8, 10, 27] . Women have been reported to have a higher degree of viremia in primary genital herpes [28] . With their larger total genital surface to be infected, women might receive a higher viral load that is forwarded to a larger number of cells within the nerve ganglions. Furthermore, factors involving the specific constitutive or adaptive immune defense may contribute to the development of symptomatic infection and/or recurrences in otherwise immunocompetent individuals [29] .
A preexisting humoral immune response to HSV-1 is a marker of protection against genital herpes [30] . The same seems true in HSV-2 meningitis according to previous observations of ours [31] . In this study, a low percentage of the patients were previously infected with HSV-1, thereby lacking this protection and at risk of meningitis when infected with HSV-2.
Considerable morbidity, comprising additional symptoms, from the CNS, PNS, and ANS occurred with and without a temporal relation to meningitis but did not differ between the groups. Recurrent limited attacks of headache without overt signs of meningitis and without CSF pleocytosis after herpes meningitis have been reported elsewhere [3, 9, 10] . In analogy with reactivation patterns in genital recurrences [32] , a nervous system viral reactivation might not always lead to migration of virus to the meninges with overt clinical meningitis but might be the basis for attacks of headache as well as transient radiating pain or skin sensitivity defects. Furthermore, recurrent attacks of meningitis may not only be followed by a sometimes protracted convalescent phase but also induce secondary symptoms such as tension headache and sleeping disturbances.
Our data do not provide support for antiviral suppression at the dosage tested (ie, 0.5 g of valacyclovir twice daily) following HSV-2 meningitis. However, it cannot be ruled out that tailored suppressive treatment may be of benefit to some patients with frequent recurrences. Further pathophysiological studies of the complex mechanisms of reactivation of HSV-2 in the CNS are desired as well as studies on suppressive antiviral treatment to prohibit recurrent meningitis. While we await a safe and effective HSV vaccine, appropriate use of antivirals is justified.
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